ATI RN
Principles of Pharmacology Quizlet Questions
Question 1 of 5
Therapeutic drug levels are drawn when a drug reaches steady state. Drugs reach steady state:
Correct Answer: B
Rationale: The correct answer is B: After four to five half-lives. Steady state is achieved when the rate of drug intake equals the rate of drug elimination, typically after 4-5 half-lives. This ensures a consistent drug level in the body. Choice A is too soon for steady state. Choice C focuses on the patient's perception, not drug kinetics. Choice D is too specific and not a general rule for all drugs.
Question 2 of 5
The Nursing Alliance for Quality Care’s focus is for health care providers to strive for which goal?
Correct Answer: C
Rationale: The correct answer is C: Development of a patient relationship/family engagement. The Nursing Alliance for Quality Care aims to promote patient-centered care, which includes building strong relationships with patients and engaging their families in the care process. This approach leads to better health outcomes and patient satisfaction. Choice A focuses on medication safety, which is important but not the primary goal of the alliance. Choice B highlights confidentiality, which is crucial but doesn't capture the alliance's main focus. Choice D emphasizes patient independence within the family, which is not directly related to the alliance's goal of patient-centered care.
Question 3 of 5
The clinical research nurse knows that only a small proportion of drugs survive the research and development process. An appreciation of the process and associated costs grows when the nurse is aware that approximately one in how many potential drugs is approved by the US Food and Drug Administration?
Correct Answer: B
Rationale: The correct answer is B: 1000. The approval rate by the FDA is around 1 in 1000 potential drugs. This means that out of a large number of drug candidates, only a very small percentage actually make it through the rigorous research and development process to receive FDA approval. Choice A (100) is too low and would imply a much higher approval rate. Choices C (10,000) and D (100,000) are too high, suggesting an even lower approval rate, which is not the case based on industry standards. Thus, the most accurate representation of the approval rate is 1 in 1000, making option B the correct answer.
Question 4 of 5
The nurse researcher reviews the proposed informed consent form for a future clinical trial. The nurse expects to find which in the document? (Select all that apply.)
Correct Answer: A
Rationale: The correct answer is A because the informed consent form should include a clear description of the benefits and risks associated with participating in the clinical trial. This information is crucial for participants to make an informed decision about their involvement. Option B is incorrect as it focuses on specific details rather than general benefits and risks. Option C is incorrect since outcomes are typically discussed after the trial, not in the initial informed consent form. Option D is incorrect as compensation details should not be included in the informed consent form to prevent coercion or inducement.
Question 5 of 5
The nurse is reviewing the drug-approval process in the United States and learns that the Food and Drug Administration Modernization Act of 1997 contains which provisions? (Select all that apply.)
Correct Answer: A
Rationale: The correct answer is A: Review of new drugs is accelerated. The FDA Modernization Act of 1997 aimed to expedite the drug-approval process by streamlining regulations and providing more efficient pathways for approval. This provision allowed for faster review of new drugs to get them to market more quickly. Choice B is incorrect because off-label use of drugs is not specifically addressed in the FDA Modernization Act of 1997. Choice C is incorrect because the privacy of individually identifiable health information is more related to HIPAA regulations rather than the FDA Modernization Act. Choice D is incorrect because the act does not require drug companies to offer advanced notice of plans to discontinue drugs.